From the American Academy of Pediatrics: Policy statements--Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections
Committee on Infectious Diseases - Pediatrics, 2009 - pubmed.ncbi.nlm.nih.gov
Palivizumab was licensed in June 1998 by the US Food and Drug Administration for
prevention of serious lower respiratory tract disease caused by respiratory syncytial virus …
prevention of serious lower respiratory tract disease caused by respiratory syncytial virus …
Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections
Committee on Infectious Diseases - Pediatrics, 2009 - publications.aap.org
This Policy Statement was retired January 2013. Palivizumab was licensed in June 1998 by
the US Food and Drug Administration for prevention of serious lower respiratory tract …
the US Food and Drug Administration for prevention of serious lower respiratory tract …
Palivizumab prophylaxis of respiratory syncytial virus disease in 2000-2001: results from The Palivizumab Outcomes Registry.
C Parnes, J Guillermin, R Habersang… - Pediatric …, 2003 - europepmc.org
The objective of the Registry was to characterize the population of infants receiving
prophylaxis for respiratory syncytial virus (RSV) disease by describing the patterns and …
prophylaxis for respiratory syncytial virus (RSV) disease by describing the patterns and …
Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV
Committee on Infectious Diseases and Committee … - …, 1998 - publications.aap.org
The Food and Drug Administration recently approved the use of palivizumab (palē-vizhū-
mäb), an intramuscularly administered monoclonal antibody preparation …
mäb), an intramuscularly administered monoclonal antibody preparation …
Palivizumab prophylaxis in infants and young children at increased risk of hospitalization for respiratory syncytial virus infection
MT Caserta, ST O'Leary, FM Munoz, SL Ralston - Pediatrics, 2023 - publications.aap.org
Guidance from the American Academy of Pediatrics (AAP) for the use of palivizumab
prophylaxis against respiratory syncytial virus (RSV) was first published in a policy statement …
prophylaxis against respiratory syncytial virus (RSV) was first published in a policy statement …
Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections
Committee on Infectious Diseases and Committee … - …, 2003 - publications.aap.org
This Policy Statement was retired October 2006. Palivizumab and Respiratory Syncytial
Virus Immune Globulin Intravenous (RSV-IGIV) are licensed by the Food and Drug …
Virus Immune Globulin Intravenous (RSV-IGIV) are licensed by the Food and Drug …
Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection
Committee on Infectious Diseases and Bronchiolitis … - …, 2014 - publications.aap.org
Guidance from the American Academy of Pediatrics (AAP) for the use of palivizumab
prophylaxis against respiratory syncytial virus (RSV) was first published in a policy statement …
prophylaxis against respiratory syncytial virus (RSV) was first published in a policy statement …
Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV
NA Halsey, JS Abramson, PJ Chesney… - …, 1998 - augusta.elsevierpure.com
Abstract The Food and Drug Administration recently approved the use of palivizumab (pale-
vizhumab), an intramuscularly administered monoclonal antibody preparation …
vizhumab), an intramuscularly administered monoclonal antibody preparation …
Effectiveness of palivizumab: evaluation of outcomes from the 1998 to 1999 respiratory syncytial virus season
M Sorrentino, T Powers… - The Pediatric …, 2000 - journals.lww.com
Background. Respiratory syncytial virus (RSV) remains a significant cause of morbidity,
especially in premature infants and immunocompromised children, resulting in …
especially in premature infants and immunocompromised children, resulting in …
[PDF][PDF] A systematic review of compliance with palivizumab administration for RSV immunoprophylaxis
M Frogel - Journal of Managed Care Pharmacy, 2010 - jmcp.org
ABSTRACT BACKGROUND: Respiratory syncytial virus (RSV) is a leading cause of lower
respiratory tract infection (LRTI) in infants and young children, accounting for approximately …
respiratory tract infection (LRTI) in infants and young children, accounting for approximately …